ADAndrew Stewart Davidson

Andrew Stewart Davidson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew Stewart Davidson has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrating training in evidence-based medicine and shared decision-making: a qualitative study of junior doctors and consultants

    by Mary Simons, Georgia Fisher, Samantha Spanos, Yvonne Zurynski, Andrew Davidson, Marcus Stoodley, Frances Rapport, Louise A. Ellis

    Background: In the past, evidence-based medicine (EBM) and shared decision-making (SDM) have been taught separately in health sciences and medical education. However, recognition is increasing of the importance of EBM training that includes SDM, whereby practitioners incorporate all steps of EBM, including person-centered decision-making using SDM. However, there are few empirical investigations into the benefits of training that integrates EBM and SDM (EBM-SDM) for junior doctors, and their influencing factors. This study aimed to explore how integrated EBM-SDM training can influence junior doctors’ attitudes to and practice of EBM and SDM; to identify the barriers and facilitators associated with junior doctors’ EBM-SDM learning and practice; and to examine how supervising consultants’ attitudes and authority impact on junior doctors’ opportunities for EBM-SDM learning and practice. Methods: We developed and ran a series of EBM-SDM courses for junior doctors within a private healthcare setting with protected time for educational activities. Using an emergent qualitative design, we first conducted pre- and post-course semi-structured interviews with 12 junior doctors and thematically analysed the influence of an EBM-SDM course on their attitudes and practice of both EBM and SDM, and the barriers and facilitators to the integrated learning and practice of EBM and SDM. Based on the responses of junior doctors, we then conducted interviews with ten of their supervising consultants and used a second thematic analysis to understand the influence of consultants on junior doctors’ EBM-SDM learning and practice. Results: Junior doctors appreciated EBM-SDM training that involved patient participation. After the training course, they intended to improve their skills in person-centered decision-making including SDM. However, junior doctors identified medical hierarchy, time factors, and lack of prior training as barriers to the learning and practice of EBM-SDM, whilst the private healthcare setting with protected learning time and supportive consultants were considered facilitators. Consultants had mixed attitudes towards EBM and SDM and varied perceptions of the role of junior doctors in either practice, both of which influenced the practice of junior doctors. Conclusions: These findings suggested that future medical education and research should include training that integrates EBM and SDM that acknowledges the complex environment in which this training must be put into practice, and considers strategies to overcome barriers to the implementation of EBM-SDM learning in practice.


  • Open Access

    OP85 Cost Effectiveness Of Prednisolone To Treat Bell’s Palsy In Children: An Economic Evaluation Alongside A Randomized Controlled Trial

    by Xiuqin Xiong, Li Huang, David Herd, Meredith Borland, Andrew Davidson, Stephen Hearps, Mark Mackay, Katherine Lee, Stuart Dalziel, Kim Dalziel, et al.

    IntroductionThe cost effectiveness of treating Bell’s palsy with prednisolone in children is unknown. This study aimed to assess the cost effectiveness of prednisolone, compared with placebo, in treating Bell’s Palsy in children from a healthcare sector perspective.MethodsThis economic evaluation was a prospectively planned secondary analysis of a triple-blind randomized superiority trial conducted from 2015 to 2020 that compared prednisolone with placebo. The time horizon was six months after randomization. The 180 participants were aged from six months to 17 years and presented within 72 hours of onset of clinician diagnosed Bell’s palsy. Interventions were oral prednisolone (1 mg per kg daily) or taste-matched placebo administered for ten days. Incremental cost-effectiveness ratios comparing prednisolone with placebo were estimated. Costs included medication costs, doctor visits, and medical tests over the six-month study period. Effectiveness was measured using quality-adjusted life-years (QALYs) derived from the Child Health Utility 9D instrument. Nonparametric bootstrapping was performed to capture uncertainties. Prespecified subgroup analyses by age (12 to 17 years versus <12 years) were performed.ResultsThe mean cost per patient was USD188 in the prednisolone group and USD121 in the placebo group over the six-month period (difference USD66, 95% confidence interval [CI]: 47, 179). The mean QALYs gained over six months were 0.45 in the prednisolone group and 0.44 in the placebo group (difference 0.01, 95%CI: -0.01, 0.03). Prednisolone was very likely cost effective given a conventional willingness-to-pay threshold of USD 50,000 per QALY gained (the cost per additional QALY gained was USD6,625 using prednisolone compared with placebo). Subgroup analysis suggested that this was primarily driven by the high probability of prednisolone being cost effective in children aged 12 to 17 years (98%), compared with those younger than 12 years (51%).ConclusionsThis study provides new evidence to stakeholders and policy makers who are considering whether to make prednisolone available for treating Bell’s palsy in children aged 12 to 17 years.


  • Open Access

    Anesthesiology

    by Evan D. Kharasch, Henry Ruth, Ralph Tovell, James E. Eckenhoff, Leroy D. Vandam, Arthur S. Keats, Nicholas P. Greene, Christopher M. Larson, John D. Michenfelder, Lawrence J. Saidman, et al.

  • Open Access

    Links between evidence-based medicine and shared decision-making in courses for doctors in training: a scoping review

    by Mary Simons, Frances Rapport, Yvonne Zurynski, Marcus Stoodley, Jeremy Cullis, Andrew S Davidson

    Objectives This scoping review aims to synthesise the current evidence on the inclusion and effectiveness of integrating evidence-based medicine (EBM) and shared decision-making (SDM) into training courses for doctors in training to enhance patient care. Both EBM and SDM appear to be taught separately and their combined role in providing high-quality patient care has not yet been explored. Design Scoping review of literature from January 2017 to June 2021. Setting Any setting where doctors in training could undertake EBM and/or SDM courses (hospitals, universities, clinics and online). Participants Doctors in training (also known as junior doctors, residents, registrars, trainees, fellows) defined as medical graduates undertaking further training to establish a career pathway. Methods Searches were conducted in the databases Medline, Embase, Scopus and Cochrane Library. Bibliographies of included articles and their cited references were hand searched and assessed for inclusion. Included studies described training and outcomes of either EBM, SDM or both. Reported outcomes included EBM knowledge and skill tests, attitude surveys, SDM checklists and surveys and patient and doctor experience data obtained from surveys, focus groups and interviews. Results Of the 26 included studies, 15 described EBM training courses, 10 described SDM training courses and 1 course combined both EBM and SDM. Courses were heterogeneous in their content and outcomes, making comparisons difficult. EBM courses prioritised quantitative outcome assessments and linked knowledge and skills, such as critical appraisal, but overlooked other key elements of patient-centred care including SDM. Conclusions SDM and EBM are taught separately in most training courses. The inclusion of SDM, evaluated by qualitative assessments, is currently omitted, yet could provide a more person-centred care focus in EBM courses and should be investigated to increase our knowledge of the effectiveness of such courses and their role in improving doctors’ skills and patient care. Protocol A protocol for this review has been published and contains further details of the methodology.


  • Open Access

    What are the links between evidence-based medicine and shared decision-making in training programs for junior doctors? A scoping review protocol

    by Mary Simons, Frances Rapport, Yvonne Zurynski, Jeremy Cullis, Andrew Davidson

    Introduction Patient-centred care is pivotal to clinical practice and medical education. The practice of evidence-based medicine (EBM) and shared decision-making (SDM) are complementary aspects of patient-centred care, but they are frequently taught and reported as independent entities. To effectively perform all steps of EBM, clinicians need to include patients in SDM conversations, however, the uptake of this has been slow and inconsistent. A solution may be the incorporation of SDM into EBM training programmes, but such programmes do not routinely include SDM skills development. This scoping review will survey the literature on the kinds of EBM and SDM educational programmes that exist for recently qualified doctors, programmes that incorporate the teaching of both EBM and SDM skills, as well as identifying research gaps in the literature. Methods and analysis Literature searches will be conducted in the databases Medline, Embase, Scopus and Cochrane Library. Bibliographies of key articles and their citing references will also be hand-searched and assessed for inclusion. Selected grey literature will be included. Papers must be written in English, or provide English abstracts, and date from 1996 to the present day. Two independent reviewers will screen titles and abstracts, check full texts of selected papers for eligibility and extract the data. Any disagreement will be resolved, and consensus reached, if necessary, with the assistance of a third reviewer. Qualitative and quantitative studies that address educational interventions for either EBM, SDM or both will be included. Data extraction tables will present bibliographic information, populations, interventions, context and outcomes. Data will be summarised using tables and figures and a description of findings. Ethics and dissemination This review will synthesise information from publicly available publications and does not require ethics approval. The results will be disseminated via conference presentations and publications in medical journals.


  • Open Access

    Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery

    by Dmitry M. Polikarpov, Douglas H. Campbell, Lucinda S. McRobb, Jiehua Wu, Maria E. Lund, Yanling Lu, Sergey M. Deyev, Andrew S. Davidson, Bradley J. Walsh, Andrei V. Zvyagin, et al.

    Glioblastoma (GBM) is one of the most aggressive tumors and its 5-year survival is approximately 5%. Fluorescence-guided surgery (FGS) improves the extent of resection and leads to better prognosis. Molecular near-infrared (NIR) imaging appears to outperform conventional FGS, however, novel molecular targets need to be identified in GBM. Proteoglycan glypican-1 (GPC-1) is believed to be such a target as it is highly expressed in GBM and is associated with poor prognosis. We hypothesize that an anti-GPC-1 antibody, Miltuximab®, conjugated with the NIR dye, IRDye800CW (IR800), can specifically accumulate in a GBM xenograft and provide high-contrast in vivo fluorescent imaging in rodents following systemic administration. Miltuximab® was conjugated with IR800 and intravenously administered to BALB/c nude mice bearing a subcutaneous U-87 GBM hind leg xenograft. Specific accumulation of Miltuximab®-IR800 in subcutaneous xenograft tumor was detected 24 h later using an in vivo fluorescence imager. The conjugate did not cause any adverse events in mice and caused strong fluorescence of the tumor with tumor-to-background ratio (TBR) reaching 10.1 ± 2.8. The average TBR over the 10-day period was 5.8 ± 0.6 in mice injected with Miltuximab®-IR800 versus 2.4 ± 0.1 for the control group injected with IgG-IR800 (p = 0.001). Ex vivo assessment of Miltuximab®-IR800 biodistribution confirmed its highly specific accumulation in the tumor. The results of this study confirm that Miltuximab®-IR800 holds promise for intraoperative fluorescence molecular imaging of GBM and warrants further studies.


  • Open Access

    Macrogonadotropinoma, a venous thromboembolic event and asymptomatic extensive periventricular white matter changes in a patient with Klinefelter syndrome

    by Divya Namboodiri, Hui Yi Ng, Aakansha Zala, John Magnussen, Andrew Davidson, Bernard Champion, Veronica Preda

    Gonadotropinoma in Klinefelter syndrome (KS) is uncommon and may be a result of protracted stimulation of gonadotrophs from lack of androgen feedback. Associations of white matter changes and increased venous thromboembolic risk have been reported and need to be considered in patients with KS.


  • Open Access

    Obstructive Hydrocephalus Due to Unruptured Brain Arteriovenous Malformation: Demonstrating Transcranial Color Duplex Confirmation of Cerebral Venous Hemodynamic Alterations and Color Duplex Ultrasound Confirmation of Shunt Patency (vol 12, e26, 2020)

    by Kathryn J. Busch, Hosen Kiat, Alberto Avolio, Mark Butlin, Andrew Davidson

    The following errors have been corrected (all located in the three paragraphs between Figures 6 and 7 in the Case Presentation section): First paragraph: "(Figure 4C)" reference removed and "(Figure 6A, 6B)" reference added. Second paragraph: "Pressure support ventilation" replaced with "peak systemic velocity", "volume" replaced with "velocity", and "(Figure 7)" reference added. Third paragraph: "VM" replaced with "mean velocity" and "(Figure 7)" reference removed.

  • Highly selective Molecularly Imprinted Polymer for creatinine detection

    by Sumedha N. Prabhu, Subhas Chandra Mukhopadhyay, Andrew S. Davidson, Guozhen Liu

    Creatinine is a metabolic waste that is constantly get diffused in the blood and filtered by the kidneys to minimize levels of waste content related to blood toxicity for maintaining a healthy balance in the living body. In the current research, we have developed a sensing polymer system for the detection of side effects of cancer chemotherapy on human kidneys for determining the creatinine levels. The proposed research is related to the real-time detection of levels creatinine in an aqueous medium. The polymer was surface characterized using Field Emission Scanning Electron Microscope (FESEM) and Energy dispersive analysis X-ray (EDAX) and found to be structurally isotropic as well as monodispersed and chemically pure in nature. Fourier-transform infrared spectroscopy (FTIR) confirmed the successful removal of creatinine from the MIP polymer by breaking Amide bonding. The sensing polymer system is able to determine concentrations within the range of 1 – 50 parts per million (ppm) when checked using ultra-high-performance liquid chromatography (UHPLC). The results highlight the future possibility of modifying this system for early levels of creatinine rise for preventing life-threatening conditions and providing indications to medical practitioners in the form of ppm unit results where they can alter the chemotherapy medications or reduce the total drug dosage to avoid health disorders such as Acute Kidney Damage and Acute Kidney Failure.


  • Interdigital sensing system for detection of levels of creatinine from the samples

    by Sumedha N. Prabhu, Subhas Chandra Mukhopadhyay, Chinthaka Gooneratne, Andrew S. Davidson, Guozhen Liu

    Creatinine is a biological waste that is diffused in the blood and filtered by the kidneys to reduce blood waste content-oriented toxicity for maintaining homeostasis in the living body. In the current research, we have developed a sensing system for early detection of side effects of brain cancer chemotherapy on human kidneys by monitoring the rise in creatinine levels. High creatinine levels can lead to permanent incurable conditions such as acute kidney damage or acute kidney failure. The proposed research is related to the real-time detection of creatinine in an aqueous medium. The sensing system is able to determine concentrations within the range of 0.1 – 50 ppm. The sensitivity % curve presented aids in finding an unknown sample concentration from resistance values at a frequency of 100 Hz using the electrical impedance spectroscopy (EIS) technique. The results highlight the future possibility of modifying this system for early levels of creatinine rise for preventing life-threatening conditions and providing indications to doctors in the form of parts per million (ppm) unit results where they can change the chemotherapy medicines or reduce the total drug regiments.